Acute Severe Asthma in Adults
Summary
Acute severe asthma is a medical emergency characterised by progressive bronchospasm, airway inflammation, and mucus hypersecretion leading to rapid respiratory deterioration. It remains a significant cause of preventable death, with approximately 3 deaths per day in the UK from asthma. The hallmark of management is early recognition of severity, aggressive bronchodilator therapy, systemic corticosteroids, and escalation to ICU when indicated.
Key Facts
- Incidence: ~100,000 hospital admissions/year in the UK; 1,500+ deaths annually
- Peak-flow: PEF <50% predicted indicates severe; <33% is life-threatening
- Golden hour: Steroids given within 1 hour reduce admission rates by 25%
- Magnesium: IV MgSO₄ reduces admissions in severe/life-threatening cases (NNT ~7)
- Silent chest: Most dangerous sign — indicates minimal air movement
- Avoid sedation: Never sedate a deteriorating asthmatic (risk of respiratory arrest)
Clinical Pearls
O SHIT M — Oxygen, Salbutamol, Hydrocortisone (or pred), Ipratropium, Theophylline, Magnesium
A "normal" or rising pCO₂ in acute asthma is a sign of impending respiratory failure (patient is tiring)
Always check inhaler technique before discharge — poor technique is the commonest cause of "brittle asthma"
Why This Matters Clinically
Acute asthma represents a unique window where rapid, protocolised intervention dramatically alters outcomes. Unlike many emergencies, the difference between good and bad outcomes is often measured in minutes. Junior doctors must be confident to escalate early when life-threatening features are present.
Incidence & Prevalence
- UK prevalence: 5.4 million people (1 in 11 adults, 1 in 5 children)
- Hospital admissions: ~100,000/year for acute exacerbations
- ICU admissions: ~1,500/year requiring intubation
- Mortality: ~1,500 deaths/year (UK); higher in those with previous ICU admission
Demographics
- Age: Bimodal — peaks in childhood and age 50-70
- Sex: Female predominance in adults (2:1)
- Ethnicity: Higher prevalence in Black Caribbean and South Asian populations
Risk Factors for Severe Exacerbation
| Risk Factor | Relative Risk |
|---|---|
| Previous near-fatal attack (ICU/intubation) | 5-10x |
| Hospital admission in past year | 3-5x |
| ≥3 ED visits in past year | 3x |
| Poor compliance / inhaler technique | 2-3x |
| NSAID / Beta-blocker use | 2x |
| Psychosocial factors (depression, denial) | 2x |
| Low socioeconomic status | 1.5x |
Seasonal Variation
- September peak: Return to school, rhinovirus circulation
- Winter: Cold air triggers, respiratory infection season
- Thunderstorm asthma: Rare but catastrophic outbreaks (e.g., Melbourne 2016)
Overview
Acute asthma exacerbation represents the acute-on-chronic failure of the inflamed airway to cope with additional triggers. The pathophysiology involves three key mechanisms working in concert:
Mechanism Cascade
1. Bronchospasm (Minutes)
- Allergen/trigger → Mast cell degranulation → Histamine + Leukotrienes
- Smooth muscle contraction → Acute airway narrowing
- Reversible with β₂-agonists
2. Airway Inflammation (Hours)
- Th2-mediated eosinophilic inflammation
- IL-4, IL-5, IL-13 release
- Mucosal oedema, vascular leak
- Requires corticosteroids for resolution
3. Mucus Hypersecretion (Hours-Days)
- Goblet cell hyperplasia
- Thick, tenacious mucus plugging
- May persist despite bronchodilation
Physiological Consequences
| Parameter | Normal | Severe Asthma | Significance |
|---|---|---|---|
| FEV₁ | 100% | <50% | Airflow obstruction |
| FRC | Normal | ↑↑ | Dynamic hyperinflation |
| pCO₂ | 5.0 kPa | ↓ initially, then ↑ | Rising = fatigue |
| pO₂ | 12 kPa | ↓ | V/Q mismatch |
| Work of breathing | Normal | ↑↑↑ | Accessory muscle use |
The "Silent Chest" Phenomenon
- Severe bronchospasm → minimal air movement → no wheeze audible
- Paradox: Improving wheeze may indicate bronchodilator response, not deterioration
- Silent chest with distress = critical emergency
Immediate Management: O SHIT M (First 15 mins)
Must be started immediately on arrival:
-
Oxygen
- High flow 15L/min via non-rebreathe mask
- Target SpO₂ 94-98%
- Do NOT withhold oxygen for fear of CO₂ retention (this is COPD)
-
Salbutamol
- Nebulised 5mg oxygen-driven (6-8 L/min)
- Repeat every 15-30 mins if needed
- Consider back-to-back nebs in severe/life-threatening
-
Hydrocortisone / Prednisolone
- Prednisolone 40-50mg PO if able to swallow
- OR Hydrocortisone 100mg IV if vomiting/severe
- Continue pred 40mg OD for 5-7 days
-
Ipratropium Bromide
- 0.5mg nebulised with salbutamol
- Add early in severe/life-threatening
- Repeat every 4-6 hours
-
Theophylline (Aminophylline)
- Consider if no response to above
- Senior decision — narrow therapeutic window
- Loading 5mg/kg over 20 mins (if not on maintenance)
-
Magnesium Sulphate
- 2g IV over 20 mins in severe/life-threatening
- Single dose; no evidence for repeat dosing
- Works within 15-30 mins
[!WARNING] Do not delay steroids — oral is as effective as IV if the patient can swallow. The earlier given, the greater the benefit.
History (Focused)
- Onset: Rapid (hours) vs Gradual (days)?
- Triggers: URTI, allergen, exercise, weather, stress, medications?
- Severity markers: Previous ICU admission? Intubation? Frequent courses of steroids?
- Medications: Current preventer compliance? Inhaler technique?
- Red flags: Confusion, inability to speak, exhaustion
Examination Findings
Inspection:
- Posture (sitting forward, tripod position)
- Respiratory rate (>25 = severe)
- Accessory muscle use (SCM, intercostals)
- Cyanosis (late sign)
- Ability to speak (sentences → words → silent)
Auscultation:
- Widespread polyphonic wheeze (expiratory > inspiratory)
- Silent chest = critical (minimal air entry)
- Localised wheeze → consider alternative diagnosis (mucus plug, foreign body)
Palpation:
- Hyperresonant percussion
- Tracheal tug (severe)
BTS/SIGN Severity Classification
| Feature | Moderate | Severe | Life-Threatening | Near-Fatal |
|---|---|---|---|---|
| PEF | 50-75% best | 33-50% best | <33% best | — |
| SpO₂ | ≥92% | ≥92% | <92% | — |
| Speech | Sentences | Phrases | Words/Silent | — |
| Heart rate | <110 | ≥110 | Arrhythmia/Bradycardia | — |
| RR | <25 | ≥25 | — | — |
| Consciousness | Normal | Normal | Altered | Coma |
| Cyanosis | No | No | Yes | — |
| ABG | — | — | Normal/↑ pCO₂ | ↓pH, ↑pCO₂ |
[!NOTE] One life-threatening feature = treat as life-threatening asthma
Bedside Investigations
| Test | Findings | Clinical Significance |
|---|---|---|
| Peak Flow (PEF) | <50% = Severe; <33% = Life-threatening | Serial measurements guide response |
| SpO₂ | <92% = Life-threatening | Continuous monitoring |
| ABG | ↓pO₂, ↓pCO₂ (early); Normal/↑pCO₂ (ominous) | Rising pCO₂ = impending arrest |
Laboratory Tests
| Test | Purpose | Expected Findings |
|---|---|---|
| ABG/VBG | Assess gas exchange, acidosis | Type 1 RF; Type 2 = failing |
| FBC | Baseline, infection | May show eosinophilia |
| U&Es | Baseline for Mg, K | Salbutamol causes hypokalaemia |
| CRP | Infection screen | Raised if infective trigger |
| Lactate | Tissue hypoperfusion | ↑ in severe cases |
Imaging
Chest X-ray — Not routine, but indicated if:
- Suspected pneumothorax (sudden pleuritic pain)
- Suspected pneumonia (fever, consolidation)
- First presentation (exclude other pathology)
- Failure to respond to treatment
CXR Findings in Acute Asthma:
- Hyperinflation (>6 anterior ribs visible above diaphragm)
- Flattened diaphragms
- Usually normal — abnormal CXR should prompt consideration of alternative diagnosis
What NOT to Do
- Do not delay treatment for investigations
- Do not perform spirometry during acute attack
- Do not order routine CXR in known asthmatic responding to treatment
BTS/SIGN Severity Classification (UK Standard)
This classification guides management intensity and disposition:
| Category | Definition | Management Level |
|---|---|---|
| Moderate Exacerbation | PEF 50-75%, no life-threatening features | ED observation, may discharge |
| Severe Acute Asthma | PEF 33-50% OR any severe feature | ED, likely admission |
| Life-Threatening Asthma | PEF <33% OR any life-threatening feature | Resus, consider ICU |
| Near-Fatal Asthma | Raised pCO₂ and/or requiring ventilation | ICU mandatory |
Severe Features (Any ONE = Severe)
- PEF 33-50% best or predicted
- Respiratory rate ≥25/min
- Heart rate ≥110/min
- Inability to complete sentences in one breath
Life-Threatening Features (Any ONE = Life-Threatening)
- PEF <33% best or predicted
- SpO₂ <92%
- Normal or raised pCO₂ (4.6-6.0 kPa)
- Silent chest
- Cyanosis
- Poor respiratory effort
- Altered consciousness
- Exhaustion
- Arrhythmia / Hypotension
Treatment Pathway by Severity
Moderate Exacerbation:
- Salbutamol 5mg neb (can use MDI + spacer: 10 puffs)
- Prednisolone 40mg PO
- Reassess at 15-30 mins
- If PEF >75% and stable → consider discharge with pred course
Severe Exacerbation:
- Oxygen 15L NRB mask
- Salbutamol 5mg neb (oxygen-driven) — repeat PRN
- Ipratropium 0.5mg neb
- Prednisolone 40-50mg PO or Hydrocortisone 100mg IV
- Admit for observation
- Consider MgSO₄ 2g IV if no response
Life-Threatening:
- Call for senior help / ICU outreach
- High-flow O₂ 15L NRB
- Back-to-back salbutamol nebs (continuous)
- Ipratropium 0.5mg neb
- Hydrocortisone 100mg IV (or pred if can swallow)
- MgSO₄ 2g IV over 20 mins
- Prepare for intubation if deteriorating
Near-Fatal / Failing Patient:
- ICU admission
- NIV (controversial — limited evidence, risk of delay)
- Intubation and ventilation
- IV Salbutamol (15mcg/min, up to 20mcg/min)
- IV Aminophylline (5mg/kg loading if not on theophylline)
- Consider IV Ketamine (bronchodilator properties)
Disposition Criteria
Safe for Discharge:
- PEF >75% predicted at 1 hour
- Stable on room air (SpO₂ >94%)
- Able to use inhalers correctly
- Written asthma action plan provided
- Prednisolone course prescribed (40mg x 5-7 days)
- Follow-up within 48 hours (GP) and 4 weeks (asthma clinic)
Admit if:
- PEF <75% at 1 hour
- Any life-threatening features
- Previous near-fatal attack
- Nocturnal exacerbation
- Pregnancy
- Social concerns / poor inhaler technique
Acute Complications
| Complication | Incidence | Presentation | Management |
|---|---|---|---|
| Respiratory Arrest | <0.5% overall; 5% of ICU admissions | Sudden apnoea, loss of consciousness | BLS/ALS, intubation |
| Pneumothorax | 1-3% | Sudden pleuritic pain, ↓ breath sounds | CXR, chest drain if tension |
| Mucus Plugging | Common | Lobar collapse, refractory hypoxia | Bronchoscopy, physiotherapy |
| Hypokalaemia | Very common | Often asymptomatic; arrhythmia risk | Monitor K, replace if <3.5 |
| Lactic Acidosis | 5-10% | ↑ Lactate, metabolic acidosis | Usually self-resolving with treatment |
Medication Complications
| Drug | Complication | Prevention/Management |
|---|---|---|
| Salbutamol | Tremor, tachycardia, hypokalaemia | Monitor HR, K levels |
| Ipratropium | Paradoxical bronchospasm (rare) | If occurs, stop and use salbutamol alone |
| Aminophylline | Arrhythmia, seizures, nausea | Check levels; avoid if on oral theophylline |
| Steroids (long-term) | Adrenal suppression, hyperglycaemia | Short courses (5-7 days) are safe |
Long-Term Consequences
- Recurrent exacerbations → airway remodelling
- Chronic steroid use → osteoporosis, diabetes, adrenal suppression
- Anxiety/PTSD following near-fatal attacks
Survival Statistics
- Overall mortality: 0.1-0.2% of acute presentations
- ICU mortality: 5-10% of intubated patients
- Post-near-fatal: 10% risk of death within 12 months if poorly controlled
Good Prognostic Factors
- Rapid response to initial bronchodilators (PEF >50% at 30 mins)
- Good inhaler technique
- Written asthma action plan
- Regular preventer use
- Never smoked
- No prior ICU admission
Poor Prognostic Factors
- Previous near-fatal attack
- Psychosocial dysfunction (denial, depression)
- Frequent oral steroid courses
- ≥3 ED visits per year
- Poor medication adherence
- Obesity
- Active smoking
Follow-Up Requirements
- 48-72 hours: GP review
- 4 weeks: Asthma specialist/nurse review
- Ongoing: Asthma action plan, annual flu vaccination, inhaler technique checks
Key Guidelines
- BTS/SIGN British Guideline on the Management of Asthma (2019) — UK standard of care. brit-thoracic.org.uk
- GINA Global Strategy for Asthma Management (2024) — International evidence synthesis. ginasthma.org
- NICE NG80: Asthma (2021) — Commissioning guidance and quality standards.
Landmark Trials
3Mg Trial (2014) — IV Magnesium in severe acute asthma
- Population: 1,109 adults with severe asthma (PEF <50%)
- Intervention: 2g IV MgSO₄ vs placebo
- Outcome: 10% absolute reduction in hospital admission (NNT 10)
- Take-home: Use MgSO₄ early in severe/life-threatening cases
SMART Programme — Symbicort Maintenance and Reliever Therapy
- Demonstrates that single low-dose ICS-formoterol inhaler reduces exacerbations vs SABA alone
- Now recommended as preferred reliever in mild-moderate asthma (GINA 2024)
Evidence Strength by Intervention
| Intervention | Evidence Level | Recommendation |
|---|---|---|
| Nebulised salbutamol | Level 1a | First-line, repeat PRN |
| Systemic corticosteroids | Level 1a | Within 1 hour of arrival |
| Ipratropium bromide | Level 1b | Add in severe/LT |
| IV Magnesium sulphate | Level 1b | Severe/LT, single dose |
| IV Aminophylline | Level 2a | Second-line, senior decision |
| Heliox | Level 3 | Limited evidence, rarely used |
What is an Asthma Attack?
An asthma attack happens when your airways suddenly become very narrow and inflamed. This makes it hard to breathe. You may feel:
- Very short of breath
- Tightness in your chest
- Wheezing (a whistling sound when you breathe)
- Unable to speak in full sentences
- Frightened or anxious
What Causes an Attack?
Common triggers include:
- Colds and chest infections (most common)
- Allergies (pollen, dust mites, pets)
- Cold air or weather changes
- Exercise
- Stress
- Smoke or strong smells
- Some medications (like ibuprofen for some people)
What Should I Do in an Attack?
- Sit up — don't lie down
- Take your blue reliever inhaler — 1 puff every 30-60 seconds, up to 10 puffs
- If you're not better after 10 puffs, or you feel worse, call 999
- If the ambulance hasn't arrived in 15 minutes, repeat 10 puffs
Warning Signs to Call 999
- You can't speak in full sentences
- Your lips or fingernails are turning blue
- Your blue inhaler isn't helping
- You feel exhausted or confused
- You're getting worse despite treatment
After Your Hospital Visit
You will be given:
- Steroid tablets to take for 5-7 days (this is safe)
- A follow-up appointment with your GP within 48-72 hours
- An appointment at the asthma clinic within 4 weeks
Preventing Future Attacks
- Take your preventer inhaler every day (usually brown, orange, or purple) — even when you feel well
- Check your inhaler technique — ask your pharmacist or nurse to watch you
- Have an Asthma Action Plan — a written plan for what to do when symptoms worsen
- Get your flu jab every year
- Avoid your known triggers where possible
- Don't smoke
Primary Guidelines
- British Thoracic Society / SIGN. British Guideline on the Management of Asthma. 2019. PMID: 31594857
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2024. ginasthma.org
- NICE. Asthma: diagnosis, monitoring and chronic asthma management (NG80). 2021. nice.org.uk/guidance/ng80
Key Studies
- Goodacre S et al. Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial. Lancet Respir Med. 2014;2(4):293-300. PMID: 24717627
- O'Driscoll BR et al. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017;72(Suppl 1):ii1-ii90. PMID: 28507176
- Kew KM et al. Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department. Cochrane Database Syst Rev. 2014;(5):CD010909. PMID: 24865567
Further Reading
- Asthma UK: asthma.org.uk
- UpToDate: Acute exacerbations of asthma in adults
- Life in the Fast Lane: Asthma